Evidence boundary

Tapering Off GLP-1s: What We Know and What We Don't

Tapering is commonly discussed, but specific taper schedules are not settled by strong clinical evidence. The safer content angle is clinician-led planning plus careful tracking.

Track clinician-directed GLP-1 transitions in Jabbit

No taper instructions: This page does not provide a taper schedule. Do not change medication timing or dose without qualified clinical guidance.

What is known

Withdrawal/extension studies show weight regain can happen after stopping GLP-1 therapy in many participants.
Obesity is often managed as a chronic condition, so maintenance strategy matters.
Specific taper methods are not proven as a universal way to prevent regain.

What to track if your clinician changes the plan

Field	Why
Plan dates	Original schedule, change date, next follow-up.
Medication timeline	Dose, interval, missed doses, restarts, switches.
Appetite	Hunger 0-10, fullness, cravings, alcohol interest.
Trend	Weekly weight average, waist, strength, steps.
Symptoms	GI symptoms, fatigue, mood, sleep, HRV, libido changes.

Sources

Related Jabbit guides

Get Jabbit on the App Store